$5.40
7.38% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

C4 Therapeutics Inc Stock price

$5.40
-0.60 9.92% 1M
-5.59 50.86% 6M
-0.25 4.42% YTD
+3.02 126.89% 1Y
-38.73 87.76% 3Y
-13.60 71.58% 5Y
-13.60 71.58% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.43 7.38%
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

Key metrics

Market capitalization $374.42m
Enterprise Value $178.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.08
P/S ratio (TTM) P/S ratio 12.74
P/B ratio (TTM) P/B ratio 1.50
Revenue growth (TTM) Revenue growth 83.26%
Revenue (TTM) Revenue $29.38m
EBIT (operating result TTM) EBIT $-116.46m
Free Cash Flow (TTM) Free Cash Flow $-78.76m
Cash position $264.10m
EPS (TTM) EPS $-1.90
P/E forward negative
P/S forward 13.17
EV/Sales forward 6.29
Short interest 18.42%
Show more

Is C4 Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

C4 Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a C4 Therapeutics Inc forecast:

5x Buy
63%
3x Hold
38%

Analyst Opinions

8 Analysts have issued a C4 Therapeutics Inc forecast:

Buy
63%
Hold
38%

Financial data from C4 Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
29 29
83% 83%
100%
- Direct Costs 7.76 7.76
3% 3%
26%
22 22
169% 169%
74%
- Selling and Administrative Expenses 25 25
0% 0%
86%
- Research and Development Expense 105 105
12% 12%
357%
-109 -109
20% 20%
-370%
- Depreciation and Amortization 7.76 7.76
3% 3%
26%
EBIT (Operating Income) EBIT -116 -116
19% 19%
-396%
Net Profit -108 -108
23% 23%
-367%

In millions USD.

Don't miss a Thing! We will send you all news about C4 Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

C4 Therapeutics Inc Stock News

Neutral
GlobeNewsWire
5 days ago
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire f...
Neutral
GlobeNewsWire
10 days ago
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences.
Neutral
GlobeNewsWire
about one month ago
Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer
More C4 Therapeutics Inc News

Company Profile

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Hirsch
Employees 145
Founded 2015
Website www.c4therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today